Impact of Pitavastatin in Hypercholesterolemic Patients With Metabolic Syndrome
- Conditions
- Metabolic SyndromeOxidative StressInflammation
- Registration Number
- NCT00444717
- Lead Sponsor
- Aichi Gakuin University
- Brief Summary
The purpose of this study is to evaluate anti-oxidative and anti-inflammatory effects of pitavastatin in hypercholesterolemic patients with the metabolic syndrome.
- Detailed Description
The metabolic syndrome is defined as a cluster of cardiovascular risk factors including visceral obesity, dyslipidemia, elevated blood pressure and impaired glucose tolerance. Recently, it has been described that oxidative stress and inflammatory reaction, which are important in progression of atherosclerosis, increases in individuals with the metabolic syndrome. Statins might have beneficial effects such as anti-oxidative and anti-inflammatory actions that are independent from their cholesterol-lowering effects. Pitavastatin, a chemically synthesized statin, has potent LDL-cholesterol lowering and also anti-oxidative and anti-inflammatory effects in animal studies. However, the effects of pitavastatin on oxidative stress and inflammatory action in patients with the metabolic syndrome have not been reported.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- Hypercholesterolemic patients
- Patients receiving lipid-lowering agents
- Familial hypercholesterolemia
- Renal disease
- Diseases of liver, gallbladder and bile ducts
- Pregnant women
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Thiobarbituric acid reactive substance; high sensitive C-reactive protein 12 weeks
- Secondary Outcome Measures
Name Time Method Total cholesterol; LDL-cholesterol; HDL-cholesterol; triglyceride; 12 weeks Homeostasis model assessment for insulin resistance; adiponectin; 12 weeks Soluble intercellular adhesion molecule-1 12 weeks
Trial Locations
- Locations (1)
Tatsuaki Matsubara
🇯🇵Nagoya, Aichi, Japan